Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2007

Xechem Receives Funding to Enhance Sickle Cell Treatment

  • Xechem International reports that Ramesh Pandey, chairman and CEO of Xechem companies, collected N350 million Naira, or $2.6 million, from Nigerian Export-Import (NEXIM) Bank. This amount is in addition to an earlier N150 million Naira, or $1.2 million, approved and disbursed by NEXIM Bank.

    “With these funds,” according to Pandey, “we can now accelerate completion of the commercial scale production facility for an opening during the fourth quarter of 2007.

    Xechem plans to use the plant to manyfacture Nicosan. It is an antisickling drug developed by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease, explains Pandey.

    While not a cure, the clinical trials have confirmed that the large majority of patients taking Nicosan no longer experience sickle cell crises while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced, he adds. Xechem says it has standardized and verified the antisickling activity of the product.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »